EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | A091215 | TEVA PHARMACEUTICALS USA
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Merck, Sharp & Dohme Corp. et al v. Teva Pharmaceuticals USA, Inc. et al 2 patentsANDA 091215efavirenz | S.D.N.Y. | 2010-03-09 | Terminated 2013-06-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$1.17
per ea
Lowest NADAC/Unit
$1.17
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00093523456EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB | $1.17 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.